SCHEMBL2226238

SCHEMBL2226238

CC(C)OC(=O)c1cccnc1N(C)[C@@H]1CCN(Cc2cccc(OC(F)(F)F)c2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 5/20 0.46
DRD2 P14416 4/20 0.46
DRD3 P35462 3/20 0.46
GMNN O75496 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
PMP22 Q01453 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CHRM4 P08173 6/20 0.46
CYP2D6 P10635 4/20 0.45
CYP3A4 P08684 2/20 0.45
TP53 P04637 1/20 0.45
SCN1A P35498 2/20 0.43
SCN8A Q9UQD0 2/20 0.43
DRD1 P21728 1/20 0.42
HTR2A P28223 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
FAAH O00519 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14632827 0.95 DRD2 (0.45) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL14554307 0.95 DRD2 (0.45) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2223998 0.91 DRD4 (0.48) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2221830 0.90 LMNA (0.53) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2223876 0.90 LMNA (0.53) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2223146 0.89 LMNA (0.50) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2223716 0.89 DRD2 (0.46) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2224199 0.89 LMNA (0.50) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2225108 0.88 LMNA (0.44) DRD4DRD2DRD3GMNNALDH1A1
SCHEMBL2224134 0.88 DRD2 (0.49) DRD4DRD2DRD3GMNNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523665-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2012-11-21 EP claimed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO claimed
EP-2729149-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2014-05-14 EP disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
WO-2013006596-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2013-01-10 WO disclosed
EP-2523665-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2012-11-21 EP disclosed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO disclosed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, KCNB2, SCNN1B DRD4 2729/4885DRD2 2023/4885DRD3 2448/4885
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, SCNN1B, TRPV1 DRD4 2850/4885DRD2 2003/4885DRD3 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.